All In Biotech

Drug Trial Radar · NCT03839771

A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy

A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy.

Last checked: Nov 19, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 968 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

968

Planned (sponsor's estimate)

Start

Mar 1, 2019

Primary completion

Apr 17, 2027

Study completion Sep 19, 2034

Sponsor

Lead sponsor
Stichting Hemato-Oncologie voor Volwassenen NederlandAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University of Ulm
First posted
Feb 15, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

AML and MDS-EB2 are malignancies of the bone marrow. The standard treatment for these diseases is chemotherapy. Patients participating have a special type of this disease because the leukemia cells (blasts) have developed an error in the genetic material (DNA). This error is called an IDH1 mutation or an IDH2 mutation (a mutation is a change in the DNA), which leads to changes in specific substances in the leukemia cells. This trial will investigate whether the addition of the new drugs Ivosidenib (for patients with IDH1 mutation) or Enasidenib (for patients with IDH2 mutation) to the standard treatment of chemotherapy controle the disease more effectively and for a longer period.

Conditions

  • Acute Myeloid Leukemia
  • Myelodysplastic Syndrome With Excess Blasts-2

Interventions

  • AG-120Drug

    250mg tablets

  • Placebo for AG-120Drug

    250mg tablets

  • AG-221Drug

    100mg tablets

  • Placebo for AG-221Drug

    100mg tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Event-free survival (EFS)Time frame: Approximately up to 60 months following first patient enrollment

Locations

181 sites in 15 countries. Site status is shown where the registry gives one.

  • AU-Adelaide-FLINDERS

    Adelaide, Australia

  • AU-Adelaide-RAH

    Adelaide, Australia

  • AU-Brisbane-PAH

    Brisbane, Australia

  • AU-Camperdown-RPA

    Camperdown, Australia

  • AU-Canberra-CANBERRAHOSPITAL

    Canberra, Australia

  • AU-Douglas-TOWNSVILLE

    Douglas, Australia

  • AU-Hobart TAS-RHOBART

    Hobart, Australia

  • AU-Launceston TAS-LAUNCESTON

    Launceston, Australia

  • AU-Melbourne-ALFRED

    Melbourne, Australia

  • AU-Melbourne-AUSTIN

    Melbourne, Australia

  • AU-Melbourne-MONASH

    Melbourne, Australia

  • AU-Melbourne-RMELBOURNE

    Melbourne, Australia

  • AU-Melbourne-SVHM

    Melbourne, Australia

  • AU-Perth-FSH

    Perth, Australia

  • AU-Perth-RPH

    Perth, Australia

  • AU-Perth-SCGH

    Perth, Australia

  • AU-Sydney-CONCORD

    Sydney, Australia

  • AU-Sydney-RNSH

    Sydney, Australia

  • AU-Sydney-SVHS

    Sydney, Australia

  • AU-Sydney-WSAH

    Sydney, Australia

  • AU-Waratah-CALVARYMATER

    Waratah, Australia

  • AT-Graz-MEDUNIGRAZ

    Graz, Austria

  • AT-Innsbruck-IMED

    Innsbruck, Austria

  • AT-Linz-ORDENSKLINIKUM

    Linz, Austria

  • AT-Vienna-HANUSCH

    Vienna, Austria

  • BE-Antwerpen-ZNASTUIVENBERG

    Antwerp, Belgium

  • BE-Brugge-AZBRUGGE

    Bruges, Belgium

  • BE-Brussel-BORDET

    Brussels, Belgium

  • BE-Brussel-UZBRUSSEL

    Brussels, Belgium

  • BE-Bruxelles-STLUC

    Brussels, Belgium

  • BE-Gent-UZGENT

    Ghent, Belgium

  • BE-Haine-Saint-Paul-JOLIMONT

    Haine-Saint-Paul, Belgium

  • BE-Hasselt-VIRGAJESSE

    Hasselt, Belgium

  • BE-Leuven-UZLEUVEN

    Leuven, Belgium

  • BE-Liege-CHRCITADELLE

    Liège, Belgium

  • BE-Liege-CHULIEGE

    Liège, Belgium

  • BE-Roeselare-AZDELTA

    Roeselare, Belgium

  • BE-Yvoir-MONTGODINNE

    Yvoir, Belgium

  • EE-Tartu-TARTU

    Tartu, Estonia

  • FI-Helsinki-HUS

    Helsinki, Finland

Showing 40 of 181 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.